



MATERIAL SAFETY DATA SHEET

Revision date: 06-Dec-2011

Version: 1.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:
1-877-777-3180

Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: AVIGRA (Sildenafil Citrate) Tablets

Trade Name: Viagra®
Synonyms: Sildenafil citrate tablets
Chemical Family: Mixture
Intended Use: Pharmaceutical product used for male erectile dysfunction

2. HAZARDS IDENTIFICATION

Appearance: Blue film-coated tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Active ingredient may be harmful if swallowed. May cause eye irritation (based on components) .

Long Term: Animal studies indicate that this material may cause adverse effects on the cardiovascular system.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include difficult digestion (dyspepsia), nose bleed, headache, flushing, insomnia, abnormal redness of skin (erythema), difficulty breathing, muscle pain, fever, gastrointestinal irritation, tingling/itching (paresthesia), transient changes in light perception and color vision, effects on hearing, and effects on vision.

EU Indication of danger: Not classified

Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Sildenafil citrate	171599-83-0	Not Listed	Xn;R22	23

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 2 of 8
Version: 1.0

3. COMPOSITION/INFORMATION ON INGREDIENTS

Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
FD & C Blue No. 2, Aluminum lake	16521-38-3	240-589-3	Not Listed	*
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	*
Triacetin	102-76-1	203-051-9	Not Listed	*
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	*
Croscarmellose sodium	74811-65-7	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash skin with soap and water. Remove contaminated clothing and shoes. If irritation occurs or persists, get medical attention. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder.
Ingestion:	Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
Inhalation:	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.
Additional Information:	Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
---------------------------------------	--

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 3 of 8
Version: 1.0

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Calcium phosphate dibasic, anhydrous	
Latvia OEL - TWA	10 mg/m ³
Sildenafil citrate	
Pfizer OEL TWA-8 Hr:	350µg/m ³
Microcrystalline cellulose	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Titanium dioxide	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 4 of 8
Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Analytical Method:

Analytical method available for Sildenafil. Contact Pfizer Inc for further information.

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:

Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Tablet

Color:

Blue

Molecular Formula:

Mixture

Molecular Weight:

Mixture

10. STABILITY AND REACTIVITY

Chemical Stability:

Stable under normal conditions of use.

Conditions to Avoid:

None known

Incompatible Materials:

As a precautionary measure, keep away from strong oxidizers

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 5 of 8
Version: 1.0

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Sildenafil citrate

Rat Oral LDmin. 300-500 mg/kg
Mouse Oral LDmin. 500-1000 mg/kg
Rat Dermal LD50 > 2000 mg/kg

Hydroxypropyl methylcellulose

Rat Oral LD50 > 10,000 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD 50 50 mg/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

Triacetin

Rat Oral LD 50 3000 mg/kg
Mouse Oral LD 50 1100 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Sildenafil citrate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Non-irritating
Skin Sensitization Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sildenafil citrate

6 Month(s) Rat Oral 3 mg/kg/day NOEL Adrenal gland, Liver, Thyroid
6 Month(s) Dog Oral 15 mg/kg/day NOEL Cardiovascular system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 6 of 8
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Sildenafil citrate

Reproductive & Fertility Rat Oral 60 mg/kg/day NOEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 50 mg/kg/day NOEL Maternal Toxicity, Not Teratogenic
Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOEL Maternal Toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sildenafil citrate

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Cytogenetics Human Lymphocytes Negative
In Vivo Micronucleus Chromosome Aberration Mouse Bone Marrow Negative

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sildenafil citrate

24 Month(s) Mouse Oral 5 mg/kg/day NOAEL Not carcinogenic
24 Month(s) Rat Oral 60 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status:

None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)
OSHA: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater .
Mobility, Persistence and Degradability: The active ingredient in this formulation is water soluble and is expected to remain primarily in water .
Bioaccumulation and Toxicity: The active ingredient in this formulation has low potential to bioaccumulate and long-term adverse effects to aquatic organisms are not expected. See aquatic toxicity data, below.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sildenafil citrate

Daphnia magna (Water Flea) TAD EC50 48 Hours 14 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 9.5 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 20 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Sildenafil citrate

Activated sludge OECD EC50 3 Hours > 1000 mg/L

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 7 of 8
Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

FD & C Blue No. 2, Aluminum lake

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	240-589-3

Lactose Monohydrate

Australia (AICS):	Present
-------------------	---------

Triacetin

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-051-9

Calcium phosphate dibasic, anhydrous

MATERIAL SAFETY DATA SHEET

Material Name: AVIGRA (Sildenafil Citrate) Tablets
Revision date: 06-Dec-2011

Page 8 of 8
Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-826-1
Croscarmellose sodium	
Australia (AICS):	Present
Hydroxypropyl methylcellulose	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
Microcrystalline cellulose	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9
Titanium dioxide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Magnesium stearate	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet